PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Net income growth under 50% of TRAW's 53.14%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
1.31%
Some D&A expansion while TRAW is negative at -100.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Both cut yoy SBC, with TRAW at -76.15%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-199.74%
Both reduce yoy usage, with TRAW at -1610.47%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth well above TRAW's 41.02%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-382.74%
Negative yoy usage while TRAW is 45.41%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-25.35%
Both negative yoy, with TRAW at -107.49%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
2.31%
Operating cash flow growth below 50% of TRAW's 25.63%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
83.69%
CapEx growth of 83.69% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
We expand invests by 83.69% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
Issuance growth of 3875.79% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.